On the same day Brazil reached the grim milestone of 250,000 deaths by COVID-19, the country’s health ministry signed a deal with Indian pharmaceutical company Bharat Biotech for the purchase of 20 million doses of the Covaxin Vaccines, which is yet to be approved by local regulators.
The administration of President Jair Bolsonaro said the first 8 million Covaxin shots, which will be made by Brazilian company Precisa Medicamentos, will arrive in March. A second batch of another 8 million doses is expected for April and in May, another 4 million doses will be available.
Also read: Brazilian President invokes Ramayana while seeking hydroxychloroquine from India
So far Brazil has vaccinated less than 4 per cent of its population of 210 million people, with some cities stopping immunization campaigns last week due to shortages.
Neither Precisa nor Bharat confirmed the deal or the delivery dates.
A letter from the Editor
Dear reader,
We have been keeping you up-to-date with information on the developments in India and the world that have a bearing on our health and wellbeing, our lives and livelihoods, during these difficult times. To enable wide dissemination of news that is in public interest, we have increased the number of articles that can be read free, and extended free trial periods. However, we have a request for those who can afford to subscribe: please do. As we fight disinformation and misinformation, and keep apace with the happenings, we need to commit greater resources to news gathering operations. We promise to deliver quality journalism that stays away from vested interest and political propaganda.
Support Quality Journalism
A letter from the Editor
Dear subscriber,
Thank you!
Your support for our journalism is invaluable. It’s a support for truth and fairness in journalism. It has helped us keep apace with events and happenings.
The Hindu has always stood for journalism that is in the public interest. At this difficult time, it becomes even more important that we have access to information that has a bearing on our health and well-being, our lives, and livelihoods. As a subscriber, you are not only a beneficiary of our work but also its enabler.
We also reiterate here the promise that our team of reporters, copy editors, fact-checkers, designers, and photographers will deliver quality journalism that stays away from vested interest and political propaganda.
Suresh Nambath